Literature DB >> 3584483

Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.

G J Kontoghiorghes, L Sheppard, A V Hoffbrand, J Charalambous, J Tikerpae, M J Pippard.   

Abstract

A novel iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, and desferrioxamine were compared for their ability to remove iron and for their site of action in iron release in rats. Repeated intraperitoneal injections of the chelators in rats with widespread tissue labelling by 59Fe derived from transferrin showed comparable 59Fe mobilisation by each chelator in normal and iron loaded rats. Specific labelling of a chelatable "cold" iron pool in hepatocytes by 59Fe derived from ferritin showed this pool to be equally accessible to parenteral doses of both chelators and also to oral 1,2-dimethyl-3-hydroxypyrid-4-one, which is an effective oral iron chelating agent that removes iron from parenchymal cells. This and other alpha-ketohydroxypyridines need further development as potential therapeutic agents in human iron overload.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3584483      PMCID: PMC1140972          DOI: 10.1136/jcp.40.4.404

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Studies on intermediary iron metabolism. V. The measurement of non-haemoglobin tissue iron.

Authors:  I KALDOR
Journal:  Aust J Exp Biol Med Sci       Date:  1954-12

2.  Storage iron kinetics. 3. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells.

Authors:  C Hershko; J D Cook; D A Finch
Journal:  J Lab Clin Med       Date:  1973-06

3.  The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.

Authors:  G J Kontoghiorghes
Journal:  Biochim Biophys Acta       Date:  1986-01-30

4.  Dose response studies using desferrioxamine and orally active chelators in a mouse model.

Authors:  G J Kontoghiorghes
Journal:  Scand J Haematol       Date:  1986-07

5.  Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.

Authors:  G J Kontoghiorghes
Journal:  Mol Pharmacol       Date:  1986-12       Impact factor: 4.436

6.  Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

Authors:  L Wolfe; N Olivieri; D Sallan; S Colan; V Rose; R Propper; M H Freedman; D G Nathan
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

7.  Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators.

Authors:  G J Kontoghiorghes
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

8.  Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.

Authors:  G J Kontoghiorghes; A V Hoffbrand
Journal:  Br J Haematol       Date:  1986-04       Impact factor: 6.998

  8 in total
  4 in total

1.  In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors:  N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Iron chelating drugs.

Authors:  G J Kontoghiorghes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-11

3.  Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94.

Authors:  P Carthew; A G Smith; R C Hider; B Dorman; R E Edwards; J E Francis
Journal:  Biometals       Date:  1994-10       Impact factor: 2.949

Review 4.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.